Hsieh, Yi-Chung <br/><br/>
Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.  [electronic resource] 

 -  PloS one  2018 
 - e0202777 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0202777  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>2-Naphthylamine<br/>Aged<br/>Aged, 80 and over<br/>Anilides--administration & dosage<br/>Antiviral Agents--administration & dosage<br/>Carbamates--administration & dosage<br/>Cohort Studies<br/>Cyclopropanes<br/>Drug Therapy, Combination<br/>Female<br/>Genotype<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Hyperbilirubinemia--chemically induced<br/>Lactams, Macrocyclic<br/>Liver Cirrhosis--drug therapy<br/>Macrocyclic Compounds--administration & dosage<br/>Male<br/>Middle Aged<br/>Proline--analogs & derivatives<br/>Prospective Studies<br/>Risk Factors<br/>Ritonavir--administration & dosage<br/>Sulfonamides--administration & dosage<br/>Sustained Virologic Response<br/>Treatment Outcome<br/>Uracil--administration & dosage<br/>Valine